Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 12, 2017 | $0.09 | 2017-11-27 | 2017-11-28 |
| September 14, 2017 | $0.09 | 2017-08-25 | 2017-08-29 |
| June 22, 2017 | $0.34 | 2017-06-01 | 2017-06-05 |
| March 20, 2017 | $0.34 | 2017-02-28 | 2017-03-02 |
| December 20, 2016 | $0.34 | 2016-12-01 | 2016-12-05 |
Dividends Summary
- Teva Pharmaceutical Industries Limited American Depositary Shares has issued 58 dividend payments over the past 14 years
- The most recent dividend was paid 2839 days ago, on December 12, 2017
- The highest dividend payed out to investors during this period was $0.350318 per share
- The average dividend paid during this period was $0.20 per share.
Company News
The global nootropics market is expected to grow from $4.98 billion in 2024 to $19.53 billion by 2034, driven by increasing interest in cognitive enhancement, mental health awareness, and rising adoption among younger professionals.
Billionaire investor Stanley Druckenmiller sold his entire Palantir stake and invested in Teva Pharmaceutical and Taiwan Semiconductor Manufacturing, showing strategic moves in the AI and pharmaceutical sectors.
Analysts forecast the global oncology drug market to exceed $900 billion by 2034, with biotech firms like Oncolytics, Teva, Citius, ADC Therapeutics, and OS Therapies driving cancer treatment innovation amid potential NCI funding cuts.
AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.